Price chart (1D to 10Y)
Licensed market data — shown to members, not published to the open web.
Valuation vs Instaport thresholds (P/E, PEG, P/FCF, P/S)
Licensed market data — shown to members, not published to the open web.
Profile
From SEC filingsCompany description
The ongoing principal business of the Company has been pharmaceutical drug development. The Company is an emerging oncology-focused biotechnology company that has a portfolio of development candidates, diversified across several distinct technologies, with the potential to yield first-in-class and best-in-class agents in a range of oncology indications. Paxalisib Kazia’s lead program is Paxalisib, (formerly known as GDC-0084), an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, that was specifically designed to treat brain cancer. Paxalisib was developed by Genentech, Inc (South San Francisco, California) and the company entered into a worldwide exclusive license for the asset in October 2016. Prior to this transaction, Genentech had completed an extensive pre-clinical development program that provided convincing validation for Paxalisib as a potential drug for brain cancer. Genentech also completed a phase I clinical trial in 47 patients with advanced recurrent grade III and grade IV glioma (NCT01547546). The most common adverse events were oral mucositis and hyperglycemia. Per ANO criteria, 40% of patients exhibited a best observable response of stable disease, and 26% demonstrated a metabolic partial response on FDG-PET. The development candidate was granted the International Non-Proprietary Name (INN) ‘Paxalisib’ by the World Health Organisation in December 2019. This was confirmed as the United States Adopted Name (“USAN”) by the USAN Council in April 2020. Paxalisib is orally administered and is presented in a 15mg capsule formulation.
Read the full filing description · filed 7 Nov 2025
At a glance
- Sector
- Healthcare
Source: SEC filings. Information and analytics, not investment advice.